Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo

Journal of Gene Medicine

Volumn 7, Issue 7, 2005, Pages 936-944

  Zavaglia, David ^a   Lin, Erh Hsuan ^a   Guidetti, Mélanie ^a   Pluquet, Olivier ^b   Hainaut, Pierre ^b   Favrot, Marie Christine ^a   Coll, Jean Luc ^a  

^a INSTITUT ALBERT BONNIOT   (France)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cancer; Gene therapy; Intercellular trafficking; P53; Protein delivery; VP22

Indexed keywords

NAKED DNA; PROTEIN P53; PROTEIN VP22;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL PROLIFERATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE TRANSFER; GENETIC ANALYSIS; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG ALVEOLUS CELL CARCINOMA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUDE MOUSE; NULL CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REPORTER GENE; SUBCUTANEOUS TISSUE TUMOR; TRANSACTIVATION; TREATMENT FAILURE; TREATMENT OUTCOME; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ARTIFICIAL GENE FUSION; CELL PROLIFERATION; CELLS, CULTURED; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENETIC VECTORS; MICE; MICE, NUDE; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIRAL STRUCTURAL PROTEINS;

HUMAN HERPESVIRUS 1; MUS MUSCULUS;

EID: 22544459966     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.741     Document Type: Article

References (37)

1. Ford KG, Souberbielle BE, Darling D, et al. Protein transduction: an alternative to genetic intervention? Gene Ther 2001; 8: 1-4.
2. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193.
3. Derossi D, Joliot AH, Chassaing G, et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10 444-10 450.
4. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-233.
5. Dilber MS, Phelan A, Aints A, et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6: 12-21.
6. Liu CS, Kong B, Xia HH, et al. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 2001; 3: 145-152.
7. Wybranietz WA, Gross CD, Phelan A, et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 2001; 8: 1654-1664.
8. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16: 440-443.
9. Wills KN, Atencio IA, Avanzini JB, et al. Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus. J Virol 2001; 75: 8733-8741.
10. Zender L, Kock R, Eckhard M, et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 2002; 123: 608-618.
11. Bennett RP, Dalby B, Guy PM. Protein delivery using VP22. Nat Biotechnol 2002; 20: 20.
12. Derer W, Easwaran HP, Leonhardt H, et al. A novel approach to induce cell cycle reentry in terminally differentiated muscle cells. FASEB J 2002; 16: 132-133.
13. Hung CF, Cheng WF, Chai CY, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001; 166: 5733-5740.
14. Oliveira SC, Harms JS, Afonso RR, et al. A genetic immunization adjuvant system based on BVP22-antigen fusion. Hum Gene Ther 2001; 12: 1353-1359.
15. Hung CF, He L, Juang J, et al. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002; 76: 2676-2682.
16. Michel N, Osen W, Gissmann L, et al. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002; 294: 47-59.
17. Leifert JA, Harkins S, Whitton JL. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther 2002; 9: 1422-1428.
18. Fang B, Xu B, Koch P, et al. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther 1998; 5: 1420-1424.
19. Aints A, Dilber MS, Smith CI. Intercellular spread of GFP-VP22. J Gene Med 1999; 1: 275-279.
20. Falnes PO, Wesche J, Olsnes S. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 2001; 40: 4349-4358.
21. Ye D, Xu D, Singer AU, et al. Evaluation of strategies for the intracellular delivery of proteins. Pharm Res 2002; 19: 1302-1309.
22. Rutjes SA, Bosma PJ, Rohn JL, et al. Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal apoptin-VP22 fusion proteins. J Mol Med 2003; 81: 558-565.
23. Lundberg M, Johansson M. Is VP22 nuclear homing an artifact? Nat Biotechnol 2001; 19: 713-714.
24. Lundberg M, Johansson M. Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 2002; 291: 367-371.
25. Zavaglia D, Favrot MC, Eymin B, et al. Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Ther 2003; 10: 314-325.
26. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
27. Coll JL, Negoescu A, Louis N, et al. Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis. Hum Gene Ther 1998; 9: 2063-2074.
28. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763-771.
29. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609-622.
30. Schuler M, Herrmann R, De Greve JL, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750-1758.
31. Chene P. The role of tetramerization in p53 function. Oncogene 2001; 20: 2611-2617.
32. Verhaegh GW, Richard MJ, Hainaut P. Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. Mol Cell Biol 1997; 17: 5699-5706.
33. Soden J, Stevens A, Ray DW. Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation. J Endocrinol 2002; 172: 615-625.
34. Zender L, Kuhnel F, Kock R, et al. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 2002; 9: 489-496.
35. Elliott G, O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther 1999; 6: 149-151.
36. Kretz A, Wybranietz WA, Hermening S, et al. HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo. Mol Ther 2003; 7: 659-669.
37. Stroh C, Held J, Samraj AK, et al. Specific inhibition of transcription factor NF-kappaB through intracellular protein delivery of I kappaBalpha by the herpes virus protein VP22. Oncogene 2003; 22: 5367-5373.